The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Share News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.00
Bid: 41.00
Ask: 43.00
Change: 0.00 (0.00%)
Spread: 2.00 (4.878%)
Open: 42.00
High: 42.00
Low: 42.00
Prev. Close: 42.00
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

Fri, 09th Jul 2021 10:52

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Cambridge Cognition Holdings PLC, up 8.1% at 177.8 pence, 12-month range 35.1p-188p. Wins GBP1 million contract as cognitive assessment partner for a late phase cancer trial. Revenue from the contract is expected to be recognised over the next six years. "This is the second contract for a top ten pharmaceutical company with a strong pipeline of oncology products," the digital neuroscience company notes.

----------

Open Orphan, up 7.4% at 26.85p, 12-month range 11.5p-48p. Subsidiary hVIVO signs "significant" contract with AIM ImmunoTech Inc to test its antiviral candidate, Ampligen, using both the human Rhinovirus HRV and Influenza human challenge study models as part of a single study. This antiviral study will be conducted by hVIVO. The pharmaceutical services firm expects majority of revenue from the contract to be recognised in the current financial year. "As previously confirmed to the market, our London facilities are comprehensively prebooked throughout this year and into next year. As such, I am also delighted to confirm that we were solidly Ebitda profitable in H1 2021 and we remain on target for a profitable and successful 2021," says Open Orphan Executive Chair Cathal Friel.

----------

AIM - LOSERS

----------

Evgen Pharma PLC, down 30% at 5.19p, 12-month range 4.22p-15.76p. The clinical stage drug development company is "surprised and disappointed" after being informed that independent data management committee concludes analyses of SFX-01 in Star Covid-19 study did not meet the interim futility hurdle required to continue the study, and that active treatment would not be likely to show an overall statistically significant improvement. Recruitment into trial to be halted. "We are surprised and disappointed by these findings given the strong preclinical hypothesis surrounding sulforaphane as an Nrf2 activator with potential direct antiviral properties," says Chief Executive Huw Jones.

----------

Empyrean Energy PLC, down 24% at 6.43p, 12-month range 3.05p-9p. The oil and gas development company raises GBP5.0 million via placing of 83.7 million shares at price of 6.0p each. "Funds raised under this placing will primarily be used to secure a suitable drilling rig and order long lead items and for the Company's general working capital requirements as it prepares to drill the Jade prospect at its 100% owned Block 29/11 license in China, scheduled for late 2021," it says.

----------

Ilika PLC, down 24% at 153p, 12-month range 56.4p-285p. The advanced solid-state battery company plans placing of up to 12.8 million shares at price of 140p each to raise GBP18.0 million. Also intends to raise up to further GBP3.7 million through open offer, and will also make retail offer for up to GBP3.0 million via PrimaryBid. In total, eyes raising total gross proceeds of GBP24.7 million. "The net proceeds of the capital raising are expected to support the development of Ilika's solid-state electric vehicle pouch cells through its Goliath programme until the programme reaches and exceeds Lithium Ion Battery equivalence," it says.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 Aug 2021 09:31

Cambridge Cognition turns in 'strong financial performance' in H1

(Sharecast News) - Software firm Cambridge Cognition said on Tuesday that it had put on a "strong financial performance" in the six months ended 30 June, with both revenue and sales growth during the period.

Read more
9 Jul 2021 11:01

Cambridge Cognition wins GBP1 million contract for cancer trial tests

Cambridge Cognition wins GBP1 million contract for cancer trial tests

Read more
9 Jul 2021 08:33

Cambridge Cognition wins £1.0m contract with 'top ten' pharma company

(Sharecast News) - Software developer Cambridge Cognition has won a £1.0m contract as the cognitive assessment partner for a late phase cancer trial.

Read more
1 Jul 2021 19:26

TRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free

TRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free

Read more
1 Jul 2021 11:31

AIM WINNERS & LOSERS: Biome Technologies plunges after profit warning

AIM WINNERS & LOSERS: Biome Technologies plunges after profit warning

Read more
28 Jun 2021 12:04

IN BRIEF: Cambridge Cognition nets GBP2.2 million contract

IN BRIEF: Cambridge Cognition nets GBP2.2 million contract

Read more
28 Jun 2021 11:17

Cambridge Cognition selected as cognitive assessment partner for large at-home study

(Sharecast News) - Cognitive assessment software provider Cambridge Cognition has been selected as the cognitive assessment partner for a large at-home study, its second such award in the last two months.

Read more
28 Jun 2021 11:16

AIM WINNERS & LOSERS: Croma Security rises on raised guidance

AIM WINNERS & LOSERS: Croma Security rises on raised guidance

Read more
14 Jun 2021 14:36

IN BRIEF: Cambridge Cognition wins GBP1.4 million in medical contracts

IN BRIEF: Cambridge Cognition wins GBP1.4 million in medical contracts

Read more
11 Jun 2021 19:50

TRADING UPDATES: Zephyr eyes US investors; Good Energy's Zap-Map boost

TRADING UPDATES: Zephyr eyes US investors; Good Energy's Zap-Map boost

Read more
2 Jun 2021 16:23

Cambridge Cognition elevates Mick Holton to executive board

(Sharecast News) - Brain health technology company Cambridge Cognition announced on Wednesday that Michael 'Mick' Holton would join the board as an executive director, with immediate effect.

Read more
2 Jun 2021 16:02

EXECUTIVE CHANGES: CEO departs after GLI Finance becomes Sancus

EXECUTIVE CHANGES: CEO departs after GLI Finance becomes Sancus

Read more
20 May 2021 16:07

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
8 Apr 2021 12:48

Cambridge Cognition wins at-home clinical trial contract

(Sharecast News) - Brain health technology company Cambridge Cognition has won a contract with a new pharmaceutical client to provide cognitive assessments in an at-home clinical trial, it announced on Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.